Insider

Amgen Inc

AMGN Health Care · 3 analyses · 9 expectations tracked

Amgen reported $10.4B in revenue (+8.5% YoY), compared with a +7.2% median across covered Health Care peers. Of 9 tracked management expectations, 2 were consistent with later reports and 0 were contradicted. Its latest periodic filing added 227 new risk factors.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

What changed

Amgen reports profit growth amid regulatory challenges

Amgen reported third quarter 2026 quarterly revenue growth of 8.5% to $10.4 billion and net income growth of 20.1% to $3.9 billion. The report also details new regulatory challenges and clinical trial results shaping the operating environment for shareholders.

· Amgen Inc

Company history

October 2026

AMGEN INC: 7 recorded developments from 2 official sources in 2026-10.

  • 2026-10-27: On October 26, 2026, Amgen's Board of Directors appointed David W. Gibbs as a director, effective immediately. Source
  • 2026-10-27: David W. Gibbs was Chief Executive Officer of Yum! Brands, Inc. from 2020 to September 2025 and has been an advisor to Yum! Brands since October 2025. Source
  • 2026-10-27: Gibbs will serve on Amgen's Audit Committee and its Compensation and Management Development Committee; the Board will have 13 directors, 12 of whom are independent. Source
  • 2026-10-27: Amgen's press release says Gibbs will serve on the Board's Audit Committee and Compensation and Management Development Committee. Source
  • 2026-10-27: The press release says Gibbs recently retired as president and chief executive officer of Yum! Brands. Source
  • 2026-10-27: Chairman and CEO Robert A. Bradway said Gibbs's experience creating direct relationships with customers will help inform how Amgen prepares for future launches. Source
  • 2026-10-27: With Gibbs's appointment, the Board will have 13 directors, 12 of whom are independent. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed November 4, 2026. SEC

LatestEarlierChange
Revenue quarter$10.4B$9.6B+8.5%
Operating income quarter$3.7B$2.5B+46.9%
Net income quarter$3.9B$3.2B+20.1%
Diluted EPS quarter$7.08$5.93+19.4%
Dividends per share quarter$2.52$2.38+5.9%
Operating cash flow year to date$10.4B$8.4B+24.9%
Cash and cash equivalents balance$13.2B$9.1B+44.5%
Long-term debt balance$51.6B$50B+3.2%

Next results expected around February 3, 2027 (estimate: the quarter ending about December 30, 2026 plus the 35 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter and the company's guidance, $B

9.1Q4 '24*25.4%8.1Q1 '2514.5%9.2Q2 '2528.9%9.6Q3 '2526.4%9.9Q4 '25*27.6%8.6Q1 '2630.9%10.1Q2 '2635%10.4Q3 '2635.8%ImpliedQ4 '26
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Amgen Inc AMGN$10.4B+8.5%35.8%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

How expectations played out

2 of 9 expectations checked against later reports

  • 2 confirmed

Mostly AI assessments, provisional; an editor's decision replaces them. Not a rating of the shares.

Checked against later reports

  • The company expects capital expenditures to be approximately $2.6 billion for the full year 2026.

    Said November 3, 2026 · Period named: full year 2026 · Source · Our article

    AI assessment, provisional later reports are consistent with it (as of November 11, 2026) · Later article

  • The company expects total revenues in the range of $38.9 billion to $39.7 billion for the full year 2026.

    Said November 3, 2026 · Period named: full year 2026 · Source · Our article

    AI assessment, provisional later reports are consistent with it (as of November 11, 2026) · Later article

Open

  • The Company plans to participate in a one-year HRSA-approved 340B rebate pilot program for ENBREL and Otezla starting in January 2027.

    Said November 4, 2026 · Period named: January 2027 · Source · Our article

    Not yet checked against later reports.

  • The Phase 3 study of dazodalibep in Sjögren’s patients (OASIZ 303) is expected to complete.

    Said November 3, 2026 · Period named: Q4 2026 · Source · Our article

    Not yet checked against later reports.

  • Two additional Phase 3 studies of MariTide in people living with T2D will be initiated.

    Said November 3, 2026 · Period named: Q4 2026 · Source · Our article

    Not yet checked against later reports.

  • Amgen plans to initiate a Phase 3 study of UPLIZNA in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) between the second half of 2026 and the first half of 2027.

    Said November 3, 2026 · Period named: H2 2026 - H1 2027 · Source · Our article

    Not yet checked against later reports.

Show all (9)
  • For the full year 2026, the company expects GAAP EPS in the range of $18.34 to $19.28 and non-GAAP EPS in the range of $22.90 to $23.70.

    Said November 3, 2026 · Period named: full year 2026 · Source · Our article

    Not yet checked against later reports.

  • Management has presented its full year 2026 EPS and tax guidance.

    Said November 3, 2026 · Period named: full year 2026 · Source · Our article

    Not yet checked against later reports.

  • The company expects share repurchases not to exceed $3.0 billion for the full year 2026.

    Said November 3, 2026 · Period named: full year 2026 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Changes in risk factors

The 10-Q filed November 4, 2026 compared with the 10-Q filed August 5, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC

Added (227)

  • in Part II herein and in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2025, and in Part II, Item 1A. Risk Factors of our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026. We have based our forward-looking statements on our management’s beliefs and assumptions based on information available to our management at the time the statements are made. We caution you that actual outcomes and results may differ materially from what is expressed, implied or forecasted by our forward-looking statements. Reference is…
  • Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. We focus on areas of high unmet medical need and leverage our expertise to strive for solutions that dramatically improve people’s lives, while also reducing the social and economic burden of disease. We helped launch the biotechnology industry more than 45 years ago and have grown to be one of the world’s leading independent biotechnology companies. Our robust pipeline includes…
  • Our principal products are Repatha, Prolia, EVENITY, TEPEZZA, ENBREL, Otezla, BLINCYTO, TEZSPIRE, Nplate, KRYSTEXXA, XGEVA, UPLIZNA, Aranesp, KYPROLIS, Vectibix and IMDELLTRA/IMDYLLTRA. We also market a number of other products, including but not limited to PAVBLU, Neulasta, AMJEVITA/AMGEVITA, MVASI, TAVNEOS, LUMAKRAS/LUMYKRAS, Parsabiv, Aimovig, PROCYSBI and WEZLANA/WEZENLA.

Dropped (55)

  • —Concentration of sales at certain of our wholesaler distributors, and consolidation of private payers, such as insurers, and PBMs has negatively affected, and may continue to negatively affect, our business. This high degree of consolidation among insurers, PBMs and other payers, including integrated healthcare delivery systems and/or with specialty or mail-order pharmacies and pharmacy retailers, has increased the negotiating leverage such entities have over us and other biopharmaceutical manufacturers and has resulted in greater price discounts, rebates and service fees realized by those…
  • —Government and commercial payer actions outside the United States have affected and will continue to affect access to and sales of our products
  • Outside the United States, we expect countries will also continue to take actions to reduce their drug expenditures and to reduce intellectual property protections. See Part I, Item 1. Business—Reimbursement, of our Annual Report on Form 10-K for the year ended December 31, 2025. Pressures to decrease drug expenditures may intensify as governments take actions to address budgets strained by high inflation and weak economic conditions, including in Europe, where sustained fiscal pressures continue to challenge public healthcare systems. In addition, policies under consideration or adopted in…

Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
October 27, 2026Director or officer departure or appointment (8-K item 5.02)8-K
July 31, 2026Material cybersecurity incident (8-K item 1.05)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock48,925,833$20,622,727,927-0.9%Q3 2026
State Street30,955,079$13,047,875,349+1.3%Q3 2026
Geode Capital Management16,041,602$6,741,585,881+2.2%Q3 2026
Capital Research Global Investors5,811,341$2,449,541,260-7.4%Q3 2026
Norges Bank (Norway's sovereign fund)5,625,584$2,037,136,478—Q2 2026
Wellington Management3,811,281$1,606,493,055+39.0%Q3 2026
Fidelity (FMR)3,603,829$1,519,050,136+3.2%Q3 2026
Citadel Advisors649,141$273,619,423-7.8%Q3 2026
D. E. Shaw & Co.405,693$171,003,656-68.6%Q3 2026
Two Sigma Investments317,977$134,030,485-71.8%Q3 2026
Millennium Management200,409$84,474,398+152.6%Q3 2026
Bridgewater Associates114,655$48,328,229+424.3%Q3 2026
T. Rowe Price5,504,356$2,320,142+39.1%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.